Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
PLoS One ; 9(10): e111302, 2014.
Article in English | MEDLINE | ID: mdl-25333658

ABSTRACT

Type I interferons (IFN) are unique cytokines transcribed from intronless genes. They have been extensively studied because of their anti-viral functions. The anti-viral effects of type I IFN are mediated in part by natural killer (NK) cells. However, the exact contribution of type I IFN on NK cell development, maturation and activation has been somewhat difficult to assess. In this study, we used a variety of approaches to define the consequences of the lack of type I interferon receptor (IFNAR) signaling on NK cells. Using IFNAR deficient mice, we found that type I IFN affect NK cell development at the pre-pro NK stage. We also found that systemic absence of IFNAR signaling impacts NK cell maturation with a significant increase in the CD27+CD11b+ double positive (DP) compartment in all organs. However, there is tissue specificity, and only in liver and bone marrow is the maturation defect strictly dependent on cell intrinsic IFNAR signaling. Finally, using adoptive transfer and mixed bone marrow approaches, we also show that cell intrinsic IFNAR signaling is not required for NK cell IFN-γ production in the context of MCMV infection. Taken together, our studies provide novel insights on how type I IFN receptor signaling regulates NK cell development and functions.


Subject(s)
Immunity, Innate , Killer Cells, Natural/metabolism , Receptor, Interferon alpha-beta/metabolism , Adoptive Transfer , Animals , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , Bone Marrow Cells/virology , Gene Expression Regulation, Developmental/genetics , Humans , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , Killer Cells, Natural/immunology , Liver/immunology , Liver/metabolism , Liver/virology , Mice , Muromegalovirus/immunology , Muromegalovirus/pathogenicity , Organ Specificity , Receptor, Interferon alpha-beta/genetics , Receptor, Interferon alpha-beta/immunology , Signal Transduction
3.
Mol Vis ; 16: 2273-8, 2010 Nov 03.
Article in English | MEDLINE | ID: mdl-21139680

ABSTRACT

PURPOSE: Age-related macular degeneration (AMD) is the most common cause of irreversible central vision loss worldwide. Research has linked AMD susceptibility with dysregulation of the complement cascade. Typically, complement factor H (CFH), complement factor B (CFB), complement component 2 (C2), and complement component 3 (C3) are associated with AMD. In this paper, we investigated the association between complement factor D (CFD), another factor of the complement system, and advanced AMD in a Caucasian population. METHODS: Six single nucleotide polymorphisms (SNPs), rs1683564, rs35186399, rs1683563, rs3826945, rs34337649, and rs1651896, across the region covering CFD, were chosen for this study. One hundred and seventy-eight patients with advanced AMD and 161 age-matched normal controls were genotyped. Potential positive signals were further tested in another independent 445 advanced AMD patients and 190 controls. χ2 tests were performed to compare the allele frequencies between case and control groups. RESULTS: None of the six SNPs of CFD was found to be significantly associated with advanced AMD in our study. CONCLUSIONS: Our findings suggest that CFD may not play a major role in the genetic susceptibility to AMD because no association was found between the six SNPs analyzed in the CFD region and advanced AMD.


Subject(s)
Complement Factor D/genetics , Genetic Association Studies , Genetic Predisposition to Disease , Macular Degeneration/genetics , Macular Degeneration/pathology , Polymorphism, Single Nucleotide/genetics , Base Sequence , Complement Pathway, Alternative/genetics , Humans , Linkage Disequilibrium/genetics , Middle Aged , Molecular Sequence Data
4.
Proc Natl Acad Sci U S A ; 107(41): 17663-7, 2010 Oct 12.
Article in English | MEDLINE | ID: mdl-20870965

ABSTRACT

The development of transgenic technologies in monkeys is important for creating valuable animal models of human physiology so that the etiology of diseases can be studied and potential therapies for their amelioration may be developed. However, the efficiency of producing transgenic primate animals is presently very low, and there are few reports of success. We have developed an improved methodology for the production of transgenic rhesus monkeys, making use of a simian immunodeficiency virus (SIV)-based vector that encodes EGFP and a protocol for infection of early-cleavage-stage embryos. We show that infection does not alter embryo development. Moreover, the timing of infection, either before or during embryonic genome activation, has no observable effect on the level and stability of transgene expression. Of 70 embryos injected with concentrated virus at the one- to two-cell stage or the four- to eight-cell stage and showing fluorescence, 30 were transferred to surrogate mothers. One transgenic fetus was obtained from a fraternal triple pregnancy. Four infant monkeys were produced from four singleton pregnancies, of which two expressed EGFP throughout the whole body. These results demonstrate the usefulness of SIV-based lentiviral vectors for the generation of transgenic monkeys and improve the efficiency of transgenic technology in nonhuman primates.


Subject(s)
Animals, Genetically Modified/genetics , Gene Transfer Techniques , Macaca mulatta/genetics , Models, Animal , Animals , Blotting, Southern , Cleavage Stage, Ovum , DNA Primers/genetics , Female , Flow Cytometry , Fluorescent Dyes , Genetic Vectors/genetics , Green Fluorescent Proteins/genetics , Immunohistochemistry , Polymerase Chain Reaction , Pregnancy , Simian Immunodeficiency Virus
5.
Mol Cancer Ther ; 9(7): 1977-84, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20571067

ABSTRACT

Proteasome inhibitor PS-341 (also known as bortezomib) and histone deacetylase (HDAC) inhibitors have emerged as novel therapeutic agents for a variety of malignancies. In this study, we examined whether PS-341 and the HDAC inhibitor trichostatin A (TSA) induced apoptosis in head and neck squamous cell carcinoma (HNSCC), a common and lethal malignancy. We found that, although TSA treatment alone did not induce apoptosis in HNSCC cells, it significantly enhanced PS-341-induced apoptosis in HNSCC cells in vitro. Consistently, TSA significantly improved PS-341-mediated inhibition of HNSCC tumor growth in nude mice. Mechanistically, we found that TSA increased PS-341-induced Noxa expression and caspase activation in HNSCC cells. The knockdown of Noxa significantly reduced apoptosis induced by cotreatment of PS-341 and TSA. Taken together, our results provide new insight into the mechanisms of synergistic antitumor activity of the PS-341 and HDAC inhibitor regimen, offering a new therapeutic strategy for HNSCC patients.


Subject(s)
Apoptosis/drug effects , Boronic Acids/pharmacology , Carcinoma, Squamous Cell/drug therapy , Head and Neck Neoplasms/drug therapy , Hydroxamic Acids/pharmacology , Pyrazines/pharmacology , Acetylation/drug effects , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blotting, Northern , Blotting, Western , Boronic Acids/administration & dosage , Bortezomib , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Caspases/metabolism , Cell Line, Tumor , Dose-Response Relationship, Drug , Drug Synergism , Enzyme Activation/drug effects , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Histone Deacetylase Inhibitors/administration & dosage , Histone Deacetylase Inhibitors/pharmacology , Histones/metabolism , Humans , Hydroxamic Acids/administration & dosage , Mice , Mice, Nude , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Pyrazines/administration & dosage , RNA Interference , Xenograft Model Antitumor Assays
6.
J Biol Chem ; 281(42): 31440-7, 2006 Oct 20.
Article in English | MEDLINE | ID: mdl-16928686

ABSTRACT

Cisplatin is one of the most common DNA-damaging agents used for treating patients with solid tumors such as squamous cell carcinoma (SCC). Unfortunately, significant levels of resistance in SCC cells emerge rapidly following cisplatin treatment. Here we report that the proteasome inhibitor PS-341, the representative of a new class of chemotherapeutic drugs, was capable of inducing apoptosis in cisplatin-resistant SCC cells via the endoplasmic reticulum stress. PS-341 stimulated the phosphorylation of PERK and the unfolded protein response, resulting in the induction of the transcription factor ATF-4. Importantly, the Bcl-2 homology domain 3-only (BH3-only) protein Noxa was found to be strongly induced in cisplatin-resistant SCC cells by PS-341 but not by cisplatin. The knock-down of Noxa using small interference RNA significantly abolished PS-341-mediated apoptosis in SCC cells. Using eIF2alpha mutant mouse embryonic fibroblasts, we found that functional eIF2alpha played an essential role in PS-341-induced Noxa expression. Taken together, our novel findings reveal a direct link between PS-341-induced endoplasmic reticulum stress and the mitochondria-dependent apoptotic pathway and suggest that PS-341 may be utilized for overcoming cisplatin-resistance in human SCC.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis , Boronic Acids/pharmacology , Carcinoma, Squamous Cell/drug therapy , Cisplatin/pharmacology , Drug Resistance, Neoplasm , Proteasome Inhibitors , Proto-Oncogene Proteins c-bcl-2/metabolism , Pyrazines/pharmacology , Animals , Bortezomib , Endoplasmic Reticulum/metabolism , Eukaryotic Initiation Factor-2/metabolism , Humans , Mice , Phosphorylation
SELECTION OF CITATIONS
SEARCH DETAIL
...